ArticleBMC cancer2022

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.

Jun Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.